12 "Genitourinary System" clinical trials found.
-
The HistoSonics Edison System for treatment of primary solid renal tumors using histotripsy (#HOPE4KIDNEY US)
This trial is a prospective, multi-center, single-arm pivotal trial designed to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of ... -
A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of livmoniplimab (ABBV-151) as a Single Agent and in Combination with budigalimab (ABBV-181) in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)
This is a Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of livmoniplimab (ABBV-151) as a ... -
A PHASE I/IB SINGLE ARM STUDY OF TWO FRACTION SBRT WITH DOMINANT LESION SIB FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER
Phase I/IB, single arm trial of Two-Fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost based on genomic classification in the ... -
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
A dose-escalation phase (phase I) is added to determine RP2D. In phase I, 3 mg/kg dose were added in the dose escalation phase, including ... -
Prospective Multicenter Single-Arm Study of Vanquish Water Vapor Ablation for PrOstate CanceR (VAPOR 2 Study)
The purpose of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation Device (“Vanquish”) in subjects with Gleason Grade ... -
A Phase II open label study of IMMU-132 in metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1/ PD-L1 based immunotherapy
This is an international, multi-center, open-label, Phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 / PD-L1 based immunotherapy ... -
Prospective Database of Clinical Outcomes Following Cryotherapy for ablation of clinically localized prostate cancer
Primary Objective: To record the treatment results and impact on clinical parameters following of Cryotherapy for ablation of clinically localized prostate cancer. Primary outcome variables ... -
INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer
This is a randomized non-inferiority trial of 6-months of gonadotropin releasing hormone (GnRH) agonist and bicalutamide plus radiation therapy (RT) versus 6-months of Darolutamide plus ... -
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH OR WITHOUT CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND OTHER TUMORS ASSOCIATED WITH PSMA EXPRESSION
This is an open-label, phase 1/2, first-in-human (FIH) study evaluating safety, tolerability, PK, and anti-tumor activity of REGN5678 (anti- PSMAxCD28) alone and in combination ... -
A Phase 3 Randomized Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with BCG in Participants with HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na ve to BCG Treatment (KEYNOTE-676)
This is a randomized, comparator-controlled, parallel-group, multi-site, open-label study of pembrolizumab in combination with BCG in participants with HR NMIBC that is persistent or recurrent ...